CIPLA

Cipla has recovered well from its May correction after weak Q4 FY26 results. The stock is currently trading around ₹1,440, still below its 52-week high of about ₹1,673. Fundamental Analysis Positives Strong leadership in respiratory, chronic therapies and domestic formulations. Healthy balance sheet with low debt. Good long-term growth drivers from India business, Africa and specialty products. Most analysts continue to maintain a Buy rating despite recent earnings weakness. The average analyst target is around ₹1,457, with some brokerages like Citi maintaining a target of ₹1,700. Concerns Q4 FY26 was weak: Revenue declined about 2.8% YoY Net profit fell about 55% YoY EBITDA margins contracted significantly Weakness was largely due to one-off issues including supply disruptions and impairment costs rather than deterioration in the core India business. Technical View Medium-term trend: Bullish Long-term trend: Positive The recent move above ₹1,400 has improved momentum. Immediate support: ₹1,370–1,390 Strong support: ₹1,300 Resistance: ₹1,500 Major resistance: ₹1,650–1,700